Lamotrigine versus levetiracetam or zonisamide for focal epilepsy and valproate versus levetiracetam for generalised and unclassified epilepsy: two SANAD II non-inferiority RCTs Lamotrigine versus levetiracetam or zonisamide for focal epilepsy and valproate versus levetiracetam for generalised and unclassified epilepsy: two SANAD II non-inferiority RCTs * Text only * * Home * Journals the use of levetiracetam or zonisamide as first line treatments in focal epilepsy or levetiracetam for newly diagnosed generalised epilepsy at 12 months. {{author}}{{author}}{{($index < metadata.AuthorsAndEtalArray.length-1) ? ',' : '.'}} Anthony G Marson, Girvan Burnside, Richard Appleton, Dave Smith, John Paul Leach, Graeme Sills, Catrin Tudur-Smith, Catrin O Plumpton, Dyfrig A Hughes, Paula R
Levetiracetam in utero: long-term effects more clearly defined Prescrire IN ENGLISH - Spotlight ''Levetiracetam in utero: long-term effects more clearly defined'', 1 December 2024 {1}##LOC[OK]## {1} ##LOC[OK]## ##LOC[Cancel]## {1}##LOC[OK]####LOC[Cancel]## Register online| Log in| My Prescrire Issue contents * Current issue * Last 12 issues * All issues Topics * Annual Prescrire Awards Subscription Rate * Subscribers: register online * Prescrire's other products * Free Special Edition * Sign up to receive the newsletter english.prescrire.org > Spotlight > 100 most recent > Levetiracetam in utero: long-term effects more clearly defined SpotlightEvery month, the subjects in Prescrire’s Spotlight. 100 most recent: 1|10|20|30|40|50|60|70|80|90 Spotlight * 100 most recent * Archives
FDA warns of rare but serious drug reaction to the antiseizure medicines levetiracetam (Keppra, Keppra XR, Elepsia XR, Spritam) and clobazam (Onfi, Sympazan) FDA warns of rare but serious drug reaction to the antiseizure medicines levetiracetam (Keppra, Keppra XR, Elepsia XR, Spritam) and clobazam (Onfi, Sympazan) | FDA * Skip to main content * Skip to FDA Search * Skip to in this section menu Drug Safety Information for Patients and Providers * Risk Evaluation and Mitigation Strategies | REMS * Safe Use Initiative * Drug Recalls * Drug Supply Chain Integrity * Multistate outbreak of fungal meningitis and other infections 1. Home 2. Drugs 3. Drug Safety and Availability 4. FDA warns of rare but serious drug reaction to the antiseizure medicines levetiracetam
Levetiracetam as an alternative to phenytoin for second-line emergency treatment of children with convulsive status epilepticus: the EcLiPSE RCT Levetiracetam as an alternative to phenytoin for second-line emergency treatment of children with convulsive status epilepticus: the EcLiPSE RCT * Text only * * Home * Journals * * Other NIHR research * * For authors * For reviewers * About * * Download report PDF * Download report documents * Download report documents * * Disclosure of interest * * * Download report XML * * Citation Tools * Print * * * * Responses to this report (0) * Permissions information View ProjectThis trial found that levetiracetam was not superior to phenytoin in the time taken to terminate convulsive status
Levetiracetam Compared With Phenytoin Or Fosphenytoin In Benzodiazepine-Refractory Pediatric Status Epilepticus HomeReviewsTherapy (NNT) ReviewsDiagnosis (LR) ReviewsAboutThe NNT, ExplainedThe NNT Rating SystemtheNNT Editorial ProcessThe NNT Intervention QuizAbout theNNT TeamSubmit an articleAccountLoginSign upContactDONATELevetiracetam Compared With Phenytoin Or Fosphenytoin In Benzodiazepine -Refractory Pediatric Status EpilepticusAssociated with similar time to seizure cessation and safety outcomesBenefits in NNTNot applicable (similar efficacy and safety)Harms in NNTNot applicable (similar efficacy and safety)View As: NNT %SourceKlowak JA, Hewitt M, Catenacci V, et al. Levetiracetam versus phenytoin or fosphenytoin for second-line treatment of pediatric status epilepticus: a meta-analysis
[ANZEN]PMDA Risk Communication: Levetiracetam, etc. posted PMDA Risk Communications | Pharmaceuticals and Medical Devices AgencyPlease make JavaScript on and see this site. * Jump to body * * * * * * * * * Navigation of each product typeOur recommended contents * for Regulatory authorities * for Healthcare professionals * for Academia * for BusinessNavigation of each product typeOur
Brivaracetam versus Levetiracetam for Epilepsy: A Review of Comparative Clinical Safety Brivaracetam versus Levetiracetam for Epilepsy: A Review of Comparative Clinical Safety | CADTH Skip to main content * About * Collaboration/Outreach * Patient/Community * Careers * Contact * My CADTH * FR * Reports * Reports * Reimbursement Review * Health Technology Review Workspaces Registration * Submit a Request * CADTH Topic Request Form * Who and What is Eligible * News & Events * News * Symposium * CADTH in Conversation with... * Events * Email: requests@cadth.ca * About * Collaboration/Outreach * Patient/Community * Careers * Contact * My CADTH Breadcrumb 1. Home 2. Brivaracetam versus Levetiracetam
Levetiracetam You need to be logged in to see the full monograph.LoginUSE OF LEVETIRACETAM IN PREGNANCYDate of issue: December 2019, Version: 3.1A corresponding patient information leaflet on USE OF LEVETIRACETAM IN PREGNANCY is available.Levetiracetam is an anticonvulsant used either in monotherapy, or as adjunctive therapy for focal or partial onset seizures with or without secondary generalisation, myoclonic seizures in juvenile myoclonic epilepsy, and primary generalised tonic-clonic seizures.Overall, congenital malformation rates have been studied in approximately 2,000 infants prenatally exposed during the first trimester to levetiracetam monotherapy, with no evidence of any increased risk, although in some cases study methodologies limit conclusions. There are also currently
Population pharmacokinetics of levetiracetam in patients diagnosed with refractory epilepsy: A real-world study. Levetiracetam is a widely used antiseizure drug in patients with refractory epilepsy due to its specific mechanism of action. This study aimed to develop and validate a population pharmacokinetic model (PopPK) to optimize levetiracetam dosing in patients with refractory epilepsy . A total of 256 plasma concentrations of levetiracetam, obtained from 135 patients, were employed for PopPK model development, applying a nonlinear mixed-effects modeling methodology. Evaluation of the final model was performed by visually inspecting the goodness-of-fit plots generated, bootstrap resampling, and visual predictive check (VPC). In addition, 60 plasma concentrations, obtained from other 37
Sudden Cardiac Death or Ventricular Arrythmia in Patients Taking Levetiracetam or Oxcarbazepine. Levetiracetam is a widely used antiseizure medication. Recent concerns have been raised regarding the potential prolongation of the QT interval by levetiracetam and increased risk of sudden cardiac death. This could have profound implications for patient safety and for prescribing practice . This study assessed the potential association of levetiracetam with cardiac outcomes related to QT interval prolongation. We compared outcomes of patients taking levetiracetam with those taking oxcarbazepine as a comparator medication that has not been associated with prolongation of the QT interval. The sample included patients who were newly prescribed levetiracetam or oxcarbazepine from January 31, 2010
Enhanced renal clearance impacts levetiracetam concentrations in patients with traumatic brain injury with and without augmented renal clearance. The purpose of this study was to examine the impact of ARC on levetiracetam concentrations during the first week following acute TBI. The hypothesis was levetiracetam concentrations are significantly lower in TBI patients with augmented renal clearance (ARC) compared to those with normal renal clearance. This is a prospective cohort pharmacokinetic study of adults with moderate to severe TBI treated with levetiracetam during the first week after injury. Serial blood collections were performed daily for analysis of levetiracetam, cystatin C, and 12-hr creatinine clearance (CrCl) determinations. Patients were divided into two cohorts: with (CrCl ≥130
Levetiracetam: a potent sword against microglia polarization in gliomas. Crosstalk between tumor cells and peritumoral cells contributes to immunosuppressive microenvironment formation in glioblastomas (GBMs). A recent study revealed that glioma stem cells activated neuronal activity to promote microglial M2 polarization for leading to GBM progression, which could be pharmacologically blocked by Levetiracetam, providing a practical strategy for GBM immunotherapy.
Safety and efficacy of levetiracetam and carbamazepine monotherapy in the management of pediatric focal epilepsy: a randomized clinical trial. Due to the limited number of studies in children with focal epilepsy and the importance of choosing the most suitable drug to control seizures in children, the administration of the most effective medication with the most negligible adverse events is vital . This study aimed to evaluate the effectiveness and adverse events of carbamazepine vs. levetiracetam monotherapy in children with focal seizures. A monocentric, randomized, controlled, double-blind, parallel-group clinical trial was designed. This study was approved by the Iranian Registry of Clinical Trials (registration number: IRCT20170216032603N2) on June 19, 2020, and conducted at the neurology
Unpacking the PEACH Trial: What is Levetiracetam’s Role in Spontaneous Intracerebral Hemorrhage? We value your privacyWe use cookies to enhance your browsing experience, serve personalized ads or content, and analyze our traffic. By clicking "Accept All", you consent to our use of cookies.CustomizeReject AllAccept AllSkip to contentMenuHOMEBLOGCASTREVIEWSPREZCRITCME/CEHCOREABOUTSEPTEMBER 7 , 2023Unpacking the PEACH Trial: What is Levetiracetam’s Role in Spontaneous Intracerebral Hemorrhage?Written by Carlton C.L. Watson, MD, MScREBEL CritMedical Category: NeurologyBACKGROUND: intracerebral hemorrhage (ICH) makes up 10-15% of all strokes and significantly contributes to overall stroke-related morbidity and mortality (Hostettler 2019). Levetiracetam is frequently used to prevent seizures
Comparison of the efficacy and safety of sodium valproate versus levetiracetam in the treatment of severe traumatic brain injury. To observe the efficacy and safety of sodium valproate (VPA) compared to levetiracetam (LEV) in the treatment of severe traumatic brain injury (sTBI). In this blind, prospective study, eighty-four sTBI patients who had craniotomy from August 2021 to August 2023 were
Comparison of the effect of phenobarbital & levetiracetam in the treatment of neonatal abstinence syndrome (NAS) as adjuvant treatment in neonates admitted to the neonatal intensive care unit: a randomized clinical trial. Infants who are born from mothers with substance use disorder might suffer from neonatal abstinence syndrome (NAS) and need treatment with medicines. One of these medicines is phenobarbital, which may cause side effects in long-term consumption. Alternative drugs can be used to reduce these side effects. This study seeks the comparison of the effects of phenobarbital & levetiracetam as adjuvant therapy in neonatal abstinence syndrome. This randomized clinical trial was performed in one year from May 2021 until May 2022. The neonates who were born from mothers with substance use
Therapeutic drug monitoring in pregnancy: Levetiracetam. Levetiracetam (LEV) is an antiseizure medication that is mainly excreted by the kidneys. Due to its low teratogenic risk, LEV is frequently prescribed for women with epilepsy (WWE). Physiological changes during gestation affect the pharmacokinetic characteristics of LEV. The goal of our study was to characterize the changes in LEV
Lamotrigine vs levetiracetam in female patients of childbearing age with juvenile absence epilepsy: A Bayesian reanalysis. Women of childbearing age with juvenile absence epilepsy (JAE) face treatment challenges due to limited access to safe and effective anti-seizure medications (ASMs). In a previous study we compared the effectiveness of levetiracetam (LEV) and lamotrigine (LTG) in women
Efficiency and safety of high-dose undiluted intravenous push levetiracetam loading doses compared to intravenous infusion in seizing patients: A retrospective cohort study. Intravenous (IV) push (IVP) is an alternative administration method for levetiracetam, but evidence evaluating it compared to IV piggyback (IVPB) for loading doses in acutely seizing patients is limited, particularly in patients with status epilepticus (SE). This study aimed to compare the efficiency and safety of IVP versus IVPB levetiracetam loading doses. This was a single-center sequential retrospective study conducted in adult (≥18 years) patients who received an IV levetiracetam loading dose (>2000 mg or ≥20 mg/kg) for acute or suspected seizure. The primary outcome was time to administration, compared between